汉斯状(HANSIZHUANG)

Search documents
复宏汉霖(02696) - 2025 H1 - 电话会议演示
2025-08-25 08:00
Financial Performance - Henlius achieved a revenue of RMB 2.82 billion in 2025 H1, representing a 2.7% year-over-year growth[5, 207, 212] - Product sales reached RMB 2.56 billion in 2025 H1, a 3.1% year-over-year increase[6, 207, 212] - The company's net profit was RMB 386 million, with a net profit margin of 13.8%[5, 6] - Net operating cash inflow reached RMB 770 million, showing a 207% year-over-year growth[6] Business Development & Out-licensing - BD contract cash inflow exceeded RMB 1 billion in 2025 H1, a 280% year-over-year growth[6] - Out-licensing deals include HLX13 (Ipilimumab) to Sandoz for up to USD 300 million, HLX15 (daratumumab) to Dr Reddy's for up to USD 131.6 million, and HANSIZHUANG (serplulimab) to Lotus in South Korea for up to USD 112 million[6, 48] - Recent major out-licensing products contributed cash inflow of approximately RMB 670 million in 1H25[47] Key Products Performance - HANSIZHUANG sales reached RMB 0.6 billion in 2025 H1[6] - HANQUYOU global revenue in 1H2025 was RMB 1.44 billion[146] - HANBEITAI revenue in 1H2025 was RMB 116 million[176] - HANNAIJIA revenue in 1H2025 was RMB 97 million[158] - HANLIKANG revenue in 1H2025 was RMB 274 million[186] - HANDAYUAN revenue in 1H2025 was RMB 27 million[186]